中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

5 records (took 0.018 seconds)

    Therapeutic and diagnostic methods for cancer
    3.
    发明授权
    Therapeutic and diagnostic methods for cancer 有权

    公开(公告)号：US11300570B2

    公开(公告)日：2022-04-12

    申请号：US16371589

    申请日：2019-04-01

    Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

    Inventor： David Fabrizio ,  Garrett M. Frampton ,  Priti Hegde ,  Marcin Kowanetz ,  David Shames ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky ,  Wei Zou

    IPC: G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  A61P35/04 ,  A61P35/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  A61K39/00

    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

    SYSTEM AND METHOD FOR MANAGING GENOMIC TESTING RESULTS
    5.
    发明申请
    SYSTEM AND METHOD FOR MANAGING GENOMIC TESTING RESULTS 审中-公开
    用于管理基因测试结果的系统和方法

    公开(公告)号：US20140336943A1

    公开(公告)日：2014-11-13

    申请号：US14146743

    申请日：2014-01-03

    Applicant: FOUNDATION MEDICINE, INC.

    Inventor： Michael Pellini ,  Gary Palmer ,  Mary P. Lancelotta ,  Matthew J. Hawryluk ,  Philip J. Stephens

    IPC: G06F19/00 ,  G06F19/22

    CPC classification number: G06F19/3456 ,  G06F19/32 ,  G06Q50/24 ,  G16B30/00 ,  G16H10/60 ,  G16H15/00

    Abstract: Various embodiments provide interfaces to access genomic testing information and incorporate it into daily physician practice. In some embodiments, presentation of genomic alteration data is simplified and/or coupled with contextual applications. Volumes of genomic alterations and associated information (e.g., journal articles, clinical trial information, therapies, etc.) are analyzed and synthesized into actionable information items viewable on an alteration system. According to one embodiment, the system can be configured to focus practitioners on discrete portions of the alteration information on which they can act. According to other aspects, curated information is provided on the system to enable practitioners to make informed decisions regarding the implications of the presence of specific genomic alterations.

    Abstract translation: 各种实施方案提供了接口以访问基因组测试信息并将其并入日常医师实践中。 在一些实施方案中，基因组改变数据的呈现被简化和/或与上下文应用相结合。 将基因组变化和相关信息（例如，期刊文章，临床试验信息，治疗等）的卷分析并合成为可变更的信息项目。 根据一个实施例，系统可以被配置为将从业者聚焦在它们可以作用于其上的变更信息的离散部分上。 根据其他方面，在系统上提供了策划的信息，以使从业者就具体基因组改变的存在的含义做出明智的决定。

Patent Agency Ranking